2026 DTRF "Together We Will" Weekend registration is OPEN. - Save your spot today!

The Desmoid Tumor Research Foundation

April 2024

Safety and efficacy of cryoablation of Soft-Tissue tumors

Author Information

Sylvain Bodard 1 2 3 4, Clement Marcelin 5, Adrian Kastler 6, Platon M Dimopoulos 1 7, Elena N Petre 1, Julien Frandon 8, Leo Razakamanantsoa 9, Francois H Cornelis 1 2 9

1Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 2Weill Cornell Medical College, 1300 York Avenue, New York, NY, 10065, USA. 3University of Paris Cité, Department of Radiology, Necker Hospital, 149 rue de Sèvre, 75015, Paris, France. 4Sorbonne University, CNRS UMR 7371, INSERM U 1146, Laboratoire d'Imagerie Biomédicale, 75006, Paris, France. 5Department of Radiology, Centre Hospitalo-Universitaire de Bordeaux, 33076, Bordeaux, France. 6Neuroradiology and MRI Unit, Grenoble Alpes University Hospital, CS10217 38043, Grenoble Cedex 09, France. 7Interventional Radiodolgy Department, University Hospital of Patras with Memorial, Greece. 8Radiology Department, Nimes University Hospital, Nimes, France. 9Sorbonne University, Department of Interventional Radiology and Oncology, Tenon Hospital, 4 rue de la Chine, 75020, Paris, France.

Publication

Br J Radiol

Summary

Objectives: To assess the safety and efficacy of percutaneous cryoablation (CA) of soft-tissue tumors (desmoid tumors (DT), vascular malformations (VM), and abdominal wall endometriosis (AWE)). Methods: This systematic review of studies published before January 2024 encompassed a detailed analysis of CA techniques and technical aspects for the treatment of soft-tissue tumors. Data concerning CA efficacy, complication rates, and other relevant metrics was extracted and included for analysis. Results: The analysis included 27 studies totaling 554 CA procedures. For DT (13 studies, 393 sessions), CA showed an average pain reduction of 79 ± 17% (range: 57-100) and a lesion volume decrease of 71.5 ± 9.8% (range: 44-97). VM (4 studies, 58 sessions) had a 100% technical success rate and an average pain reduction of 72 ± 25% (range: 63-85). The average pain reduction for AWE (6 studies, 103 sessions) was 82 ± 13% (range: 62-100). Overall, the complication rate for CA was low, with minor adverse events (AE) in about 20% of patients and major events in less than 5% of patients. Conclusion: Showing substantial efficacy in pain reduction and lesion volume decrease, as well as low incidence of severe AE, CA presents as a highly effective and safe alternative for the treatment of soft-tissue tumors. Advances in knowledge: CA is effective and safe in treating soft-tissue tumors, particularly DT, VM, and AWE.

View Abstract